Tengbo Li’s Post

🚀 Big News in MedTech! 🚀 AcuityMD has secured $45M in Series B funding to expand its innovative commercial intelligence platform for medical technology manufacturers! 🌟💡 This round was led by ICONIQ Growth, with participation from Atreides Management, LP, StepStone Group, and existing investors Redpoint Ventures Inc, Benchmark Capital, and Artisanal Ventures. To date, AcuityMD has raised over $83M, achieving a remarkable 10x increase in annual recurring revenue since its 2022 Series A raise. 📈💰 Key Highlights: 🔹 AcuityMD's platform transforms healthcare data into actionable insights, driving more than 25% sales growth for top reps and creating over $10B in opportunity pipeline. 🔹 Supporting over 200 MedTech manufacturers, including six of the top 10 globally. 🔹 Plans to launch three new products, expand the pipeline management solution, and grow the engineering and product teams by 70% by the end of 2024. 🚀🔬 "AcuityMD is a market leader in commercial MedTech software with powerful data and prospecting insights that have elicited positive feedback from customers," said Tengbo Li, Partner at ICONIQ Growth. With the backing of experienced MedTech executives and financial partners, AcuityMD is set to accelerate the adoption of cutting-edge medical technology, bringing new treatments to patients faster. 🏥💉 #MedTech #Funding #HealthcareInnovation #CommercialIntelligence #AcuityMD #ICONIQGrowth #TechInnovation #StartupSuccess 🚀🔬💰

In this #throwback, we delve into the bittersweet inspiration that drove Doug Evans, CEO of Lungpacer Medical. He shares his decades of experience launching startups, developing products, working with payers & regulators, and commercializing novel technologies. Meanwhile, Mike Kujak, CEO of Francis Medical, talks about developing the alpha & beta versions of a #medicaldevice and how best to plan & execute a clinical research strategy. (Links to both interviews in the comments section.) Here’s a sneak peek at two of our exclusive interviews: 𝟯 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗚𝗼𝗮𝗹𝘀 𝗘𝘃𝗲𝗿𝘆 𝗡𝗲𝘄 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲 𝗦𝗵𝗼𝘂𝗹𝗱 𝗔𝗶𝗺 𝗙𝗼𝗿: 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗗𝗼𝘂𝗴 𝗘𝘃𝗮𝗻𝘀, 𝗖𝗘𝗢 𝗼𝗳 𝗟𝘂𝗻𝗴𝗽𝗮𝗰𝗲𝗿 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 🚨 Why clinicians initially preferred a simpler device with high complication rate over Lungpacer’s earlier iteration with best-in-class clinical data. ⚗️ The trifecta formula that Doug uses to assess the success of a new medtech device. 🚑 Doug’s mantra that expedited FDA’s Emergency Use Authorization during Covid-19: Ensure the benefits outweigh any risks to patients.    𝗛𝗼𝘄 𝘁𝗼 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝘇𝗲 𝗳𝗼𝗿 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 & 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗠𝗶𝗸𝗲 𝗞𝘂𝗷𝗮𝗸, 𝗖𝗘𝗢 𝗼𝗳 𝗙𝗿𝗮𝗻𝗰𝗶𝘀 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 🏎️ How race car engines inspired Francis Medical's water vapor technology to treat prostate diseases. 💉 How Francis’ engineers implemented the design-prototype-redesign cycle by working alongside physicians. 🧮 Mike’s formula for building a scientific advisory board. PS - We recently launched exciting new features exclusively for Medsider premium members: ⭐ Playbooks: Go from 0 to 100 with hand-picked collections of the best Medsider interviews with the brightest founders and CEOs. ⭐ Investor database: Find your next medical device or health technology investor with our growing database of VC funds, equity investors, and high-net-worth angels.

Exciting news! BlakeBrooke Ventures has added Empress Medical to its portfolio. This game-changing technology in the treatment of uterine fibroids is much needed and wanted. As they approach their 4th round fundraiser, I strongly encourage investors to consider this innovative solution. The team behind Empress Medical is incredibly experienced, having worked together on numerous successful projects with multiple exits. Dr. Tal's technology provides better patient outcomes in a less invasive and simpler way. The women's health market is booming with innovation, and now is the time to support these phenomenal advancements. Keep an eye out for the commercial release of this technology in the US. If you're interested in investing or have any questions, feel free to message me and I'll connect you. Please note that this document reflects statements that may constitute forward-looking statements and projections that are subject to risks and uncertainties, including information about possible or assumed future events, results of economic conditions and Empress Medical business, results of operations, plans and objectives. These statements are based on personal beliefs, assumptions and expectations of Empress Medical future performance, taking into account information currently available to it. You should not place undue reliance on such statements, as new risks and uncertainties may arise and it is not possible to predict those events or how they may affect Empress Medical

Bonfire Analytics Raises Oversubscribed $2M Venture Round to Accelerate Digital Health, Medical Device, & Biotech Adoption Across Healthcare Providers | Healthcare IT Today - Healthcare IT Today #BonfireAnalytics Raises $2M to Accelerate Healthcare Adoption #VentureRound Oversubscribed for Bonfire Analytics #Accelerating Digital Health, Medical Device, & Biotech Adoption #Healthcare Providers Benefit from Bonfire Analytics #Digital Health Innovation Supported by Bonfire Analytics #Medical Device Adoption Boosted by Bonfire Analytics #Biotech Solutions Enhanced by Bonfire Analytics #Bonfire Analytics: Driving Healthcare Transformation #Healthcare IT Professionals: Stay Updated with Bonfire Analytics ai.mediformatica.com #health #analytics #healthtech #bonfireanalytics #healthcare #digital #medical #platform #providers #biotech #digitalhealth #medicaldevice #healthit #healthcaretechnology @MediFormatica (https://buff.ly/4bPb7Vu)

🤝How to collaborate with huge healthcare institutions like Kaiser Permanente ? Had the chance to attend a great panel of Kaiser Executives in Berkeley, California : Kevin L. Hart, Sande Irwin, Chris Stenzel and Sandra Pham moderated by Cathy Farmer. I learned that Kaiser is organized through a National Product Council (NPC) that is sourcing new products for Kaiser through all divisions : oncology, imaging, telehealth.. with a focus on the "shift to the right" from inpatient to outpatient Some key learnings that can be applied to any collaboration with big corporate 🎰"Spread your bets" : talk to multiple clinicians, executives within the company to validate your value proposition 🚪"Don't treat any clinician as a sure bet to put your foot in the door" 🔄"Understand entreprise wide implementations of your tech in terms of IT, compliance..." - holistic approach 🏃♂️🏃♀️"Build relationships over time" "it is not a sprint it is a marathon" Valuable to all B2B startups ! thanks Kaiser Permanente and University of California, Berkeley Berkeley SkyDeck

NEW: This month's Expert Q&A brings together some of the brightest minds and boldest innovations in the ESKD landscape. Bringing a medical device to market in this space is a herculean feat that requires more capital, grit, teamwork, and patience than most people realize. Today we aim to demystify that process a bit, focusing on progress, pitfalls, and potential in this corner of the Kidneyverse. Let's meet the device experts: John E. Milad - Fmr. CEO, Quanta Dialysis Technologies Michael Serle - Clinical Director, Mozarc Medical Cynthia Silva, M.D. - VP Clinical Affairs, Outset Medical, Inc. Alexander Hassan - Head of Product, Mendaera, Inc. Eric S. - CEO, SeaStar Medical David Narrow - CEO, Sonavex 𝐖𝐡𝐚𝐭 𝐲𝐨𝐮'𝐥𝐥 𝐥𝐞𝐚𝐫𝐧: • Current state of ESKD devices / market • Barriers to effective ESKD treatments • Recommended solutions to deice barriers • How policy & regulatory factors weigh-in • Future directions and opportunities • Personal insights and anecdotes • Resources and discussion These 6 experts represent a broad range of firsthand experiences and insights. They have founded, led, and advised companies at every stage of the commercial lifecycle. Today, they shape the visions and strategies of products that aim to improve patients’ lives across the globe. I’m grateful for their leadership and for sharing their earned wisdom with all of us today. *** Please join me in saying thank you to today's experts. And if you learn something new or want to share your thoughts, please like, comment, and share this report with people in your network! #healthcare #innovation #medtech #funding #startups https://lnkd.in/egPP3hkH

In this article about MedTech trends for 2024, I was struck by this line, because it has ALWAYS been true: "We expect Medtech companies that can link revenue to successful patient outcomes to continue to capture a significant portion of Medtech venture funding..." That has certainly been true for the firms I've been fortunate enough to consult for! https://lnkd.in/gxMrdQMQ

COMMUNITY PHARMACIES ARE AT A CROSSROADS Grappling with the possibility of closure due to the "lost leader strategy" employed by some market players. Sustaining business has become a significant challenge for these pharmacies. The current wave of mergers and acquisitions is a result of the capitalistic economy and the availability of cheap funds. The medical retail industry is further undergoing disruption through digital initiatives such as "Online Pharmacy Platforms," telemedicine, and e-prescriptions. With the increasing integration of automation and AI, there arises a pertinent question: can robots replace the role of pharmacists? As the world transitions from a VUCA (Volatility, Uncertainty, Complexity, and Ambiguity) to a BANI (Brittle, Anxious, Nonlinear, Incomprehensible) environment, opportunities often emerge amidst crises. The key lies in spotting and leveraging these opportunities. How can community pharmacies stay focused and perform well despite the numerous distractions and crises?

In today’s Medsider Premium edition, Scott Wolf, MD, founder of Aerin Medical, shares his experience as a prolific medtech entrepreneur and investor.   And Bob Paulson, CEO of Sonex Health, talks about NXTHERA, INC.’s exit to Boston Scientific and other key learnings from his storied medical device career. (link to interviews in comment section) Here’s a sneak peek at two of our exclusive interviews: 𝗧𝗮𝗸𝗲 𝗬𝗼𝘂𝗿 𝗠𝗲𝗱𝘁𝗲𝗰𝗵 𝗜𝗱𝗲𝗮 𝗳𝗿𝗼𝗺 𝗭𝗲𝗿𝗼 𝘁𝗼 𝗢𝗻𝗲: 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗗𝗿. 𝗦𝗰𝗼𝘁𝘁 𝗪𝗼𝗹𝗳, 𝗙𝗼𝘂𝗻𝗱𝗲𝗿 𝗼𝗳 𝗔𝗲𝗿𝗶𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 🥩 How Scott completed Aerin’s early feasibility work, including animal tissue from the butcher, for less than $100k. 💡 Scott's decision-making process when building Aerin's clinical and regulatory roadmap. 𝗠𝗶𝘀𝘁𝗮𝗸𝗲𝘀 𝘁𝗼 𝗔𝘃𝗼𝗶𝗱 𝗶𝗻 𝗘𝗮𝗿𝗹𝘆-𝗦𝘁𝗮𝗴𝗲 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲 𝗗𝗲𝘃��𝗹𝗼𝗽𝗺𝗲𝗻𝘁: 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗕𝗼𝗯 𝗣𝗮𝘂𝗹𝘀𝗼𝗻, 𝗳𝗼𝗿𝗺𝗲𝗿 𝗖𝗘𝗢 𝗼𝗳 VentureMed Inc. 💸 Bob's 4 keys to capital raising: compelling value proposition, market opportunity, emphasizing the unmet need, and a clear path to get to the finish line. 😟 Bob's 3 prototyping pitfalls: fuzzy end goal, lack of physician input, and pursuing perfection. PS - We recently launched exciting new features exclusively for Medsider premium members: ⭐ Playbooks: Go from 0 to 100 with hand-picked thematic collections of the best Medsider interviews with the brightest founders and CEOs. ⭐ Investor database: Find your next medical device or health technology investor with our database of 700+ VC funds, equity investors, and high-net-worth angels.

NEW: This month's Expert Q&A brings together some of the brightest minds and boldest innovations in the ESKD landscape. Bringing a medical device to market in this space is a herculean feat that requires more capital, grit, teamwork, and patience than most people realize. Today we aim to demystify that process a bit, focusing on progress, pitfalls, and potential in this corner of the Kidneyverse. Let's meet the device experts: John E. Milad - Fmr. CEO, Quanta Dialysis Technologies Michael Serle - Clinical Director, Mozarc Medical Cynthia Silva, M.D. - VP Clinical Affairs, Outset Medical, Inc. Alexander Hassan - Head of Product, Mendaera, Inc. Eric S. - CEO, SeaStar Medical David Narrow - CEO, Sonavex 𝐖𝐡𝐚𝐭 𝐲𝐨𝐮'𝐥𝐥 𝐥𝐞𝐚𝐫𝐧: • Current state of ESKD devices / market • Barriers to effective ESKD treatments • Recommended solutions to deice barriers • How policy & regulatory factors weigh-in • Future directions and opportunities • Personal insights and anecdotes • Resources and discussion These 6 experts represent a broad range of firsthand experiences and insights. They have founded, led, and advised companies at every stage of the commercial lifecycle. Today, they shape the visions and strategies of products that aim to improve patients’ lives across the globe. I’m grateful for their leadership and for sharing their earned wisdom with all of us today. Read the full Q&A here: https://lnkd.in/egPP3hkH *** Please join me in saying thank you to today's experts. And if you learn something new or want to share your thoughts, please like, comment, and share this report with people in your network! #healthcare #innovation #medtech #funding #startups